Familial Gastric Cancer Study

  • Research type

    Research Study

  • Full title

    Prospective multicentre study to investigate clinical and molecular stratification of patients with genetic predisposition to gastric cancer

  • IRAS ID

    349750

  • Contact name

    Rebecca Fitzgerald

  • Contact email

    rcf29@cam.ac.uk

  • Sponsor organisation

    Cambridge University Hospitals and University of Cambridge

  • Duration of Study in the UK

    2 years, 4 months, 1 days

  • Research summary

    Diffuse-type stomach cancer is very aggressive and, by the time it has progressed to a stage when it causes symptoms in a patient, can be difficult to cure. People with a first-degree relative diagnosed with stomach cancer have a higher risk, but it is difficult to precisely estimate this risk. Some people with family history of diffuse-type stomach cancer have a faulty gene identified, usually CDH1, as part of a genetic syndrome called Hereditary Diffuse Gastric Syndrome. These individuals require close monitoring with endoscopy (camera test) and often are recommended to have surgery to remove their stomach in order to prevent them from developing cancer. However, more than half of the people with a faulty CDH1 gene will never develop cancer. Having the stomach removed is a major operation with often serious, life-changing short and long-term consequences, yet it remains the only way to remove the risk of developing stomach cancer in people affected by with Hereditary Diffuse Gastric Cancer. Therefore, it is important to conduct more research to help doctors distinguish between those patients who truly need this operation, and those whose risk can be managed through endoscopic surveillance . We propose to collect clinical information, tissue and blood samples and videos of endoscopic procedures to perform research analyses to improve the knowledge on familial gastric cancer, develop better tests to estimate the cancer risk and new options to prevent cancer from developing and understand the impact of surgery on patients’ lives.

  • REC name

    West Midlands - South Birmingham Research Ethics Committee

  • REC reference

    25/WM/0166

  • Date of REC Opinion

    22 Oct 2025

  • REC opinion

    Further Information Favourable Opinion